Jove
Visualize
Contact Us

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

158
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
158
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

192
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
192
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

220
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
220
Cancer Therapies02:49

Cancer Therapies

7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
  1. Home
  3. Real-world Trae Association Between Niraparib And Platinum-based Chemotherapy.
  1. Home
  3. Real-world Trae Association Between Niraparib And Platinum-based Chemotherapy.

Related Experiment Video

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents
07:20

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents

Published on: May 28, 2014

14.0K

Real-world TRAE association between niraparib and platinum-based chemotherapy.

Linli Wang1, Jieli Zhou2, Haibin Wang2

  • 1First Clinical College, Gannan Medical University, Ganzhou, China.

Frontiers in Oncology
|July 2, 2024

View abstract on PubMed

Summary
This summary is machine-generated.

Patients with advanced ovarian cancer tolerated niraparib well, experiencing fewer treatment-related adverse events, particularly anemia and decreased neutrophil counts, compared to platinum-based chemotherapy. Careful monitoring is advised for hematological adverse reactions during niraparib treatment following chemotherapy.

Keywords:
PARPichemotherapyhematologic adverse reactionsniraparibovarian cancerplatinum drugs

More Related Videos

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.5K
Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

8.7K

Related Experiment Videos

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents
07:20

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents

Published on: May 28, 2014

14.0K
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.5K
Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

8.7K

Area of Science:

  • Oncology
  • Pharmacology
  • Genitourinary Cancer

Background:

  • PARP inhibitors (PARPi) and platinum agents share DNA damage repair pathway mechanisms, suggesting overlapping sensitivity.
  • Pre-clinical data indicate patients responding to platinum-based chemotherapy may also benefit from PARPi.

Purpose of the Study:

  • To evaluate the association of treatment-related adverse events (TRAE) between platinum-based chemotherapy (PBC) and niraparib in advanced ovarian cancer patients.
  • To assess the real-world safety profile of niraparib following platinum-based chemotherapy.

Main Methods:

  • Retrospective analysis of 40 advanced ovarian cancer patients treated with niraparib (maintenance or salvage) from January 2020 to August 2023.
  • Documented adverse events during the last cycle of platinum-based chemotherapy and during niraparib treatment.
  • Utilized Fisher's exact test for correlation analysis of TRAE.

    • Main Results:

    • Overall grade ≥3 TRAE were significantly lower with niraparib (40%) compared to chemotherapy (70%), notably anemia (20% vs 45%) and decreased neutrophil counts (17.5% vs 57.5%).
    • Any grade TRAE were also significantly lower with niraparib (75%) versus chemotherapy (100%), including decreased white blood cell count (47.5% vs 87.5%), red blood cell count (57.5% vs 92.5%), anemia (55% vs 87.5%), and neutrophil count (35% vs 85%).
    • No new safety signals were identified during niraparib treatment.

    Conclusions:

    • Patients with advanced ovarian cancer tolerated niraparib well, showing significantly lower rates of TRAE, including anemia and neutropenia, compared to prior platinum-based chemotherapy.
    • Close monitoring and management of hematological adverse reactions are recommended for patients receiving niraparib after experiencing grade ≥3 hematological adverse events during platinum-based chemotherapy.